Cencora, Inc. · NYSE:COR
Cencora — AmerisourceBergen — Investor Day (December 2010)
117 slides from Cencora's investor day presentation, Dec 16, 2010
Slide 1: Welcome to Investor Day December 16, 2010
1 Welcome to Investor Day December 16, 2010
Slide 2: Dave Yost, Chief Executive Officer
2 Dave Yost Chief Executive Officer
Slide 3: Comment Regarding Forward Looking Statements
Comment Regarding Forward Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's cu
Slide 4: Agenda
Agenda Dave Yost Chief Executive Officer 36 Years Steve Collis President & Chief Operating Officer 16 Years James Frary President ABSG Distribution Services 3 Years Peyton Howell President Consulting Services 19 Years Tony Pera Senior Vice President Supply Chain 4 Years Mike DiCandilo Executive Vice
Slide 5: AmerisourceBergen
AmerisourceBergen Delivering Every Day
Slide 6: AmerisourceBergen Growth Drivers
Have not changed for several years Laser focus, no distractions AmerisourceBergen Growth Drivers Generics Specialty
Slide 7: Diversity within our $80B revenues
Delivering Every Day Diversity within our $80B revenues (CHART) (CHART) Generic Customer
Slide 8: ABC Diversification
ABC Diversification Customer Base Products Services Suppliers
Slide 9: EPS from Continuing Operations CAGR
17% CAGR GAAP Basis +14% Earnings Per Share from Continuing Operations (GAAP) +17% +31% +20% 20% CAGR 24% CAGR
Slide 10: Year Stock Performance
1 Year Stock Performance H) AmerisourceBergen
Slide 11: Bloomberg Businessweek Fifty Best Performing Companies
5 Year Stock Performance Bloomberg Businessweek Fifty Best Performing Companies on 5 Year Return
Slide 12: Fortune Total Return to Investors, Last 10 Years
10 Year Stock Performance #22 Fortune 500 Total Return to Investors, Last 10 Years
Slide 13: Some Recognition Since Last Year
Some Recognition Since Last Year
Slide 14: Some Recognition Since Last Year
Some Recognition Since Last Year 2010 VIP Award for Value Innovation Performance from Our Largest Customer
Slide 15: Organizational Changes Since Last Year
Tearing down the walls Organizational Changes Since Last Year Steve Collis Founder ABSG James Frary Former RVP ABDC Peyton Howell Founder Lash Delivering Every Day
Slide 16: Tearing Down Walls
Tearing Down Walls Drug Company North Region South Region East Region West Region Canada Technology Solutions Specialty Distribution and Services Oncology Supply ION Besse ASD ICS US Bio Consulting Services Lash Xcenda Clinical Services Packaging Group American Health Packaging Anderson Packaging Br
Slide 17: New ABC Organization
Single Point of Leadership Focus Ease of Manufacturer Interface Maximization of Offerings/Assets Cross-pollenization New ABC Organization Delivering Every Day
Slide 18: Steve Collis, President & COO
18 Steve Collis President & COO AmerisourceBergen
Slide 19: Steve Collis, President, COO
Steve Collis President, COO AmerisourceBergen Drug Company Specialty Distribution and Services Consulting Services Packaging Group Delivering Every Day North Region South Region East Region West Region Canada Technology Solutions 4,700 associates Oncology Supply ION Besse ASD ICS US Bio 1,600 associ
Slide 20: Tremendous Performance in FY2010
Drug Company Consulting Services Packaging Group Delivering Every Day Above market revenue growth Strong contribution from generics Continued margin expansion Increased expense & efficiency leverage Strong revenue growth Unprecedented contribution from generics Exceptional margin improvement Strong
Slide 21: Diverse Businesses
Drug Company Consulting Services Packaging Group Delivering Every Day Drug distribution in US & Canada to retail, hospital, & alternate site Credit management for manufacturers Integrated solution portfolio PBM/Payor relationships through GNPPN Drug distribution Physician offices Clinics Practice ma
Slide 22: Tearing Down Walls
Drug Company Consulting Services Packaging Group Delivering Every Day Efficiency, operational excellence; Prime Vendor relationships Innovative services, physician networks Adherence strategies, enhanced manufacturer services Sophisticated solutions for life of product, clinical trial and beyond; HU
Slide 23: Tearing Down Walls
Delivering Every Day Tearing Down Walls Clinical expertise of Xcenda/Lash helping with adherence and persistency work in ABDC retail network Joint strategy in oncology for both hospitals and community clinics Retail client penetration and differentiated offering Collaborative efforts on legislative
Slide 24: Deliver shareholder value
Delivering Every Day Deliver shareholder value Collaborate to drive innovation for providers and manufacturers Increase customer and supplier value Expand our business in targeted markets Maximize operating efficiency through cross- company collaboration
Slide 25: James Frary, President, Specialty Distribution and Services
25 James Frary President AmerisourceBergen Specialty Distribution and Services
Slide 26: ABSG At A Glance
ABSG At A Glance NY) AmerisourceBergen AmerisourceBergen’ Specialty Group DIASD Healthcare: Dics AmerisourceBergen Specialty Group AmerisourceBergen Specialty Group D) Besse Medical DUS Bioservices AmerisourceBergen Specialty Grouy ‘AmerisourceBergen Specialty Group pecialty Group »)) Oncology Suppl
Slide 27: Essential Partner for Specialty Rx
Essential Partner for Specialty Rx Delivering unique value to the supply chain Tangible cost & quality benefit Value-added solutions for providers & manufacturers Trusted partner Proven track record of enhancing collaboration among pharma, providers, payers Delivering Every Day
Slide 28: Ongoing Growth in Specialty
Ongoing Growth in Specialty Source: 2010-2014 IMS Market Prognosis North America USA (WAC Rx Purchases) Rx Market Forecast Growth (2009-2014) Non-specialty 4% Specialty 6% Oncology 7% Other Specialty 5%
Slide 29: ABSG Revenue Strength: Oncology and More
ABSG Revenue Strength: Oncology and More (CHART)
Slide 30: Undisputed Leader in Specialty Product Distribution
Undisputed Leader in Specialty Product Distribution Largest oncology products distributor More than half of all community-based oncologists in US Leading distributor in dialysis Largest blood plasma products distributor Strong position in ophthalmology Delivering Every Day
Slide 31: Specialty Generics Opportunities
Specialty Generics Oxaliplatin First major oncology injectible to go generic Contributed $0.25 of EPS FY11 Gemcitabine (Nov 15th) & Docetaxel FY12 Oxaliplatin returns (August 2012) FY13 Oxaliplatin (full-year), Zometa Excellent Opportunities in FY2011 and Beyond Historic Performance in FY2010 Delive
Slide 32: Biosimilar Opportunity
Biosimilar Opportunity ABSG extremely well positioned for biosimilars Biosimilars would likely require our targeted services e.g. Market access services, infusion, Compliance/persistency programs, REMS Process and timing of product approvals TBD Delivering Every Day
Slide 33: Trusted Partner
Trusted Partner History of leadership in specialty Scale, breadth, quality Unparalleled service & flexibility Focused on customer success
Slide 34: Broad Solutions
Broad Solutions Leading distribution and GPO services Pharmacy and patient management solutions Clinical data and informatics Tools to optimize provider efficiency and support payer-provider quality initiatives Collaborative innovation leveraged across specialty distribution & consulting
Slide 35: Provider Solutions
Provider Solutions Comprehensive technology suite that allows physicians and their staff to optimize clinical, operational and financial performance Clinical Performance Inventory Management Financial Management Claims Management Integration with leading EMRs, clinical pathways, e-prescribing and pr
Slide 36: Provider Solutions
Provider Solutions ^ Oncology Nurse (Practice Administrator, Office Staff) Billing Staff (Practice Administrator, Physician) Practice Administrator (Physician, Nurses, Billing Staff) Physician, Nurse (Practice Administrator, Billing Staff)
Slide 37: Quality Initiatives in Oncology
Quality Initiatives in Oncology Clinical Pathways Total Patient Care Support clinically sound treatment alternatives for specific clinical diagnoses Provide tools and infrastructure for electronic interface with payers Address aspects of the treatment decisions beyond the drug regimen Patient-centri
Slide 38: Quality Initiatives
Quality Initiatives Physician centric: keep community oncologists central to care model ABSG does not intervene between payers and providers ABSG provides the infrastructure and support needed for success Clinical pathways suggested in six, "high volume" disease states Payers and providers modify pa
Slide 39: Summary
Summary Specialty has a great future Overall market growth New generics launches Growth in biosimilars We're poised to continue our specialty leadership Breadth, depth, and continuity Quality service and customer satisfaction Trusted relationships We have a great vision for the future Cross-function
Slide 40: Peyton Howell, President, Consulting Services
40 Peyton Howell President, AmerisourceBergen Consulting Services and SVP Business Development
Slide 41: A trusted, essential partner to manufacturers
A trusted, essential partner to manufacturers Lash Group - 20 years of market experience, recognized leader of market access support line services Xcenda - Dramatic growth from health outcomes and economics to comprehensive pharmaceutical brand and managed markets consulting Now selling and contract
Slide 42: Consulting Services
Consulting Services Market differentiation - integrated expertise that directly aligns with manufacturers' commercial objectives. From early stage development to market maturity.
Slide 43: Proving Value: Health Outcomes and Payer Strategy
Proving Value Health Outcomes and Payer Strategy Product was 2nd in class of a new generation of drugs that were disease-modifying and was seeking market differentiation based on health outcomes Manufacturer Need Multiple retrospective database studies showed in commercial- and government-funded pop
Slide 44: Maximizing Access: Reimbursement Hub Program
Maximizing Access Reimbursement Hub Program Launch of an injectable product into primary care and specialty created a need for centralized and streamlined reimbursement and patient support services. Reimbursement hub program provides a single point of contact to support patient access to care. Geogr
Slide 45: Integrated Services
Integrated Services Developed to specific disease state needs to support commercialization and maximize patient access to care All data for all services housed in a single integrated system Adherence Services and Relationship Marketing Co-pay Assistance Program Patient Assistance Program Reimburseme
Slide 46: Maximizing Access: Field Reimbursement Services
Launch of a physician administered injectable product into primary care created a need for services addressing practice concerns to initiate treatment. Deploy team of field based reimbursement and practice management experts to support product launch and market expansion. Unique value proposition si
Slide 47: Improving Adherence
Hepatitis C product with current baseline compliance of 73% across all specialty pharmacies. Designed and implemented nurse patient education and adherence program. Opt-in program included compliance risk assesment and lab result monitoring. In its first year, patients enrolled in the program had a
Slide 48: Double-digit revenue CAGR
Double-digit revenue CAGR, last 5 years Continued growth driven by emerging regulatory and health policy trends Risk Evaluation and Mitigation Strategies (REMS) Focus on health outcomes and patient adherence Changing coverage and reimbursement landscape New HIT data sources create new analytic oppor
Slide 49: Leading Market Position
Unmatched scale and breadth of services Both market access consulting and comprehensive patient access support services Over 1,000 consulting engagements for 133 pharmaceutical, biotech and medical device companies in 2010 Manage 108 programs for 41 different manufacturers Over 2,000 seat call cente
Slide 50: Concluding Thoughts
Our service offering has shifted from a "nice to have" to an essential component of product commercialization strategies Fundamental for all new product launches; Supports longevity of mature products Health reform brings new focus on health outcomes and value messaging across all payer types Reimbu
Slide 51: Steve Collis, President & COO
51 Steve Collis President & COO AmerisourceBergen
Slide 52: ABDC Overview
$60+ billion in revenue Committed exclusively to the delivery of pharmaceutical care Brands, generics, HBA and OTC Programs and services to help customers and suppliers reduce costs increase revenue improve efficiency enhance patient care Delivering Every Day ABDC Overview
Slide 53: Supply Chain Efficiency and Prime Vendor
Manufacturers Dispensers Supply Chain Efficiency Value Prime Vendor Security Delivering Every Day
Slide 54: Prime Vendor Value
Daily Delivery to over 22,000 delivery points Credit Management Inventory Management Prime Vendor Value to Manufacturers Prime Vendor Value to Customers Daily Delivery of all products, low admin cost Provide financing Inventory Management Security Data (supply chain transparency) Security Data & pha
Slide 55: ABDC FY10 Financial Highlights
Delivering Every Day Outstanding Performance ABDC revenues up 10% Gross margin up Expenses flat Operating margin up Excellent management of working capital ABDC FY10 Financial Highlights
Slide 56: cE2 Philosophy Remains Key
Delivering Every Day cE2 Philosophy Remains Key Customer Efficiency - Cost Effectiveness Does the customer need the service Are we providing it at the best value Continuous Improvement of overall customer experience
Slide 57: Continuous Improvement in Operations
Continuous Improvement in Operations Efficiency Focus Customer Shipping Packet Track & Trace | RFID Business Continuity Systems Courier | Delivery Standardization Cold Chain Delivery ABCC OPTIMIZ Delivering Every Day
Slide 58: Continued Productivity Improvements
Delivering Every Day Continued Productivity Improvements Lines per Hour Expense per Line Lines per Hour Expense per Line
Slide 59: Diverse customer base
Delivering Every Day Diverse customer base ABDC ABDC Generic Customer - -- Drives generic Scale
Slide 60: PRxO Generics
Access to over 7,000 generic items Minimize the time & cost of dealing with multiple generics suppliers Realize the total economic and innovative value offering of the PRxO(r) Generics solution Achieve higher long term profits PRxO(r) Generics Delivering Every Day
Slide 61: How do we grow generics faster than the market?
Expanded emphasis beyond retail Customized portfolios Targeted incentives Everyday low prices First to shelf Quality, consistency of supply Telesales Vigorous contract and compliance process How do we grow generics faster than the market? Delivering Every Day
Slide 62: Retail Independents & Regional Chains
Delivering Every Day - Retail Independents & Regional Chains Help community pharmacists attract new patients, improve retention and medication adherence, and drive down operating costs Continuously improve generics offering and drive enhanced compliance and penetration Help customers prepare for upc
Slide 63: Pharmacy Performance Dashboards
Pharmacy Performance Dashboards Key Performance Indicators - Store Comparison to Peers Delivering Every Day -- Retail
Slide 64: GNPPN Store Count
3,700- GNP Members Nationwide 746 982 1,175 749 2007 2008 2009 2010 GNPPN Store Count 2008 2009 2010 Delivering Every Day -- Retail
Slide 65: Hospitals & Health Systems
Delivering Every Day - Health Systems Hospitals & Health Systems Quality Care Solutions for greater efficiency and better patient outcomes Market Growth Solutions to expand patient base and community reach Cost Control Solutions to enhance profitability Improving generic penetration
Slide 66: Hospital and Health Systems Solutions
66 Cost Control Solutions Quality Care Solutions Market Growth Solutions Hospital and Health Systems Solutions Performance Assessment Inventory Management Pharmacy Transition Execution Integrated Services Center Medication Process Medication Policy Medication Tracking Coordinated Patient Care Enterp
Slide 67: Alternate Site: Broad, Fast Growing Market
Broad, Fast Growing Market Long Term Care Behavioral Health Pharmacy Health Maintenance Organization (HMO) Pharmacy Mail Order Pharmacy Specialty Pharmacy Home Infusion Home Healthcare Clinic Services Dialysis Surgery Center Rehabilitation Veterinary Pharmacy Delivering Every Day - Alternate Site
Slide 68: Diverse Solutions for a Diverse Market
Diverse Solutions for a Diverse Market Opportunities for Innovation Differentiated generics offering Best practices from across our networks Targeted consulting and technology solutions to drive efficiency Multi-Segment experience from cross company expertise Delivering Every Day - Alternate Site
Slide 69: Innovating to Meet Customer Needs
Innovating to Meet Customer Needs Customer Efficiency Customer Experience Cost Effectiveness Productivity and Effectiveness Customer Satisfaction Ratings The Next Generation of Customer Care Delivering Every Day -- ABDC
Slide 70: ABDC BT Update
Delivering Every Day -- ABDC BT Update Go live launched successfully October 1 We are running back office on SAP Customers move to SAP beginning in early summer
Slide 71: Focus for FY11
Delivering Every Day Focus for FY11 Grow revenue with the market 3-5% Grow generics above market Enhance programs and services Leverage expense dollars
Slide 72: Tony Pera, SVP Supply Chain Management
72 Tony Pera Senior Vice President, Supply Chain Management
Slide 73: Tony Pera
25+ years in Generics Co-founder Bedford Laboratories (acquired by Boehringer- Ingelheim) Former head of US generics business of APP (acquired by Kabi Fresenius) Joined ABC as President, American Health Packaging in 2006 SVP Supply Chain Management early 2008 Tony Pera Delivering Every Day
Slide 74: Generics
AmerisourceBergen Generics
Slide 75: Robust Generics Growth
Branded patent expirations All payers aggressively promoting use of generics to reduce healthcare costs Increased awareness and acceptance Generic dispensing rates continue to rise More access to coverage Greater medication adherence Robust Generics Growth Delivering Every Day
Slide 76: US Generic Scripts Continue to Grow
Delivering Every Day Delivering Every Day US Generic Scripts Continue to Grow Source: IMS Health
Slide 77: Patent Expirations
Patent Expirations Lipitor Zyprexa Plavix* Seroquel* Actos* Aricept Taxotere Gemzar Levaquin* Zometa Oxycontin* Aciphex* Niaspan* Cymbalta Nexium* Celebrex* Actonel* Actonel* Actonel* Actonel* Actonel* * 2nd half of year Delivering Every Day
Slide 78: Economics of Generic vs. Branded
Delivering Every Day Make as much or more gross profit dollars per unit on generics Reduced receivable risk Reduced working capital Can negotiate better terms, ie 60 days DPOs Produces higher ROCC Economics of Generic vs. Branded Holds true even after exclusivity periods
Slide 79: The Generics Market Dynamics
Two players in 6-month exclusivity period Authorized generic (AG) Exclusive generic Limited players with hard-to-make drug Complexity One player in 6-month exclusivity period Multiple players in easy-to-make drug Day 181 The Generics Market Dynamics Delivering Every Day
Slide 80: The Right Customer Mix
Retail Healthcare Providers Regional drugstore chains Food/Drug combination Independent pharmacies Institutional Healthcare Providers Hospital Long Term Care/Alternate Site Specialty Physician Oncology/Rheumatologist/Ophthalmologist The Right Customer Mix Delivering Every Day
Slide 81: Generics Philosophy
Generics Philosophy Monitor and react to industry trends Manage PRxO(r) Generics Program Procure products from reliable sources Provide manufacturers market access Deliver optimal value to customers Market shortages Support the Prime Vendor Model Delivering Every Day
Slide 82: PRxO Generics
Formulary that consists of over 6,500 SKUs Value pricing Portfolio management Tailored programs address specific customer needs Focused on customer profitability Dynamic market response 100+ manufacturers in PRxO(r) generics Key component of Prime Vendor Model PRxO(r) Generics Delivering Every Day
Slide 83: Generics Manufacturers
Increasing transparency with manufacturers Provide inventory and sales data (TruVu(tm)) Building stronger relationships Transition from transactional to collaborative Targeted & staggered bidding process Global Scope Routinely conduct international site visits Attention to quality and supply history
Slide 84: Pharmaceutical Services Value
Pharmaceutical Services Value *Includes inventory ownership, recalls, and reverse logistics Delivering Every Day
Slide 85: Branded Pharmaceuticals
» AmerisourceBergen Branded Pharmaceuticals
Slide 86: Branded Product Environment
FDA approvals and R&D pipelines weak Focus on Specialty Patent expirations $95 billion over next 5 years Increased government pressure and scrutiny Price increases have been aggressive Consolidation continues Branded Product Environment Delivering Every Day
Slide 87: The Status of Fee For Service
Effectively all manufacturers covered FFS renewals continue to pay us for the value we provide FFS metric performance near 100% 10% of GP now subject to price fluctuation Retained value with large pharmaceutical company mergers The Status of Fee For Service Delivering Every Day
Slide 88: Manufacturer Benefits: Inventory Control and Delivery
Inventory Control Smooth and predictable demand Key to supply chain safety Delivery of Products Deliveries to 22,000 ship-to-points per day 99+% customer service levels Pick/pack/ship approximately 6,600 SKUs branded products Manufacturer Benefits Delivering Every Day
Slide 89: Manufacturer Benefits: Credit Management and Data
Credit Management Assume down channel credit risk and cash collections for customer base Prime Vendor Model reduces risk Data Inventory data Available daily Invoice level sales data Available daily Marketing and promotion effectiveness Manufacturer Benefits Delivering Every Day
Slide 90: Pharmaceutical Services Value
Pharmaceutical Services Value *Includes inventory ownership, recalls, and reverse logistics Delivering Every Day
Slide 91: Pharmaceutical Services Value
Pharmaceutical Services Value (CHART) Delivering Every Day
Slide 92: Summary
Generics Business is healthy Robust growth period ABC has the right customer mix Brand FFS environment is stable Prime Vendor Model is stronger than ever Summary Delivering Every Day
Slide 93: Mike DiCandilo, EVP & Chief Financial Officer
93 Mike DiCandilo Executive Vice President & Chief Financial Officer
Slide 94: Financial Review
AmerisourceBergen Financial Review
Slide 95: Long Term Financial Goals
Long Term Financial Goals EPS growth of approximately 15% Revenue growth with market Operating margin expansion ROIC>WACC Free cash flow approximates net income Minimum 30% of free cash returned to shareholders Delivering Every Day
Slide 96: EPS from Continuing Operations CAGR
96 96 17% CAGR GAAP Basis +14% Earnings Per Share from Continuing Operations (GAAP) +17% +31% +20% 20% CAGR 24% CAGR
Slide 97: Revenues 6% CAGR
(CHART) Revenues 6% CAGR Delivering Every Day Billions
Slide 98: Operating Margin Expansion
(CHART) Operating Margin Expansion bps +8 +6 +7 +5 +16 Delivering Every Day
Slide 99: Asset Management
Asset Management Asset Management Inventory Days A/R Days Delivering Every Day Days
Slide 100: Return on Invested Capital
Delivering Every Day Return on Invested Capital (CHART) WACC
Slide 101: Cash Generation and Deployment
Cash Generation Cash Generation Acquisitions Share Repurchases Free Cash Flow Income from Continuing Operations (CHART) / Deployment billions Delivering Every Day
Slide 102: Fiscal Year 2010 Results
$2.22 diluted EPS from continuing operations, up 31.4% including a $0.05 gain from litigation $78.0 billion record revenue, up 8.6% 1.42% Operating Margin, up 19 basis points Strong generic performance Expense control leverage Cash flow from operations of $1.1 billion, up 41.4% Fiscal Year 2010 Resu
Slide 103: Fiscal Year 2011 Targets
Fiscal Year 2011 Targets GAAP Diluted EPS of $2.31 to $2.41, up 7% to 12% over $2.16, which is diluted EPS achieved in FY2010 less litigation gains Total revenue growth of 2% to 4% Operating Margin expansion in the low to mid single digit basis points range Free cash flow of $625 to $700 Million Inc
Slide 104: EPS Growth Estimate FY11 Drivers
EPS Growth Estimate Increase over FY10 EPS less litigation gains or $2.16 7-12% EPS Growth +Share repurchase $400 million - -Net interest expense up as much as 20% 2-3% Cash Deployment 5-9% Op Inc Growth +Expense leverage +Generics - -Customer mix - -Duplicate IT Expense/BT 3-5% Margin Expansion +Ma
Slide 105: EPS Impact of Key Specialty Generics
Delivering Every Day EPS Impact of Key Specialty Generics Year Product(s) Contribution FY2009 Oxaliplatin $0.05 FY2010 Oxaliplatin $0.25 FY2011 OxaliplatinGemcitabineDocetaxel $0.25+
Slide 106: Fiscal Year 2011 Targets by Business Unit
Fiscal Year 2011 Targets Revenue Growth and Operating Margin by Business Unit Business Unit % of Revenue Revenue Growth ABDC ABSG ABPG ABCG Total 3% - 5% - -5% - 0% 5% - 10% 10% - 12% 2% - 4% 79% - 82% 18% - 20% <1/2% <1/2% 100% Operating Margin Range 1.15% - 1.20% 2.10% - 2.20% 10% - 12% 10% - 12%
Slide 107: Fiscal 2011 Capital Deployment
What's Available? $1.7 billion of cash @ 9/30/10 ($1.1 billion available) Free Cash Flow of $625-$700 million expected for FY11 Total available for investment about $1.7 billion - $1.8 billion, excluding additional borrowing capacity Where to deploy? $400 million of shares expected to be repurchased
Slide 108: Strong, consistent performance
Delivering Every Day Strong, consistent performance Fantastic 2010 Solid forecast for 2011 despite tough comparison Great financial flexibility
Slide 109: Dave Yost, Chief Executive Officer
109 Dave Yost Chief Executive Officer
Slide 110: The Road Ahead for ABC
AmerisourceBergen The Road Ahead for ABC
Slide 111: The ABC Circle of Life
The more drugs they take The older they get The more drugs they take The older people get The ABC Circle of Life Alive and well and truer than ever.
Slide 112: EPS from Continuing Operations CAGR
112 112 17% CAGR GAAP Basis +14% Earnings Per Share from Continuing Operations (GAAP) +17% +31% +20% 20% CAGR 24% CAGR
Slide 113: AmerisourceBergen EPS
FY01 through FY10: +17% GAAP FY10: A blow out year, +31% GAAP FY11: +7% - 12% (on top of FY10!) AmerisourceBergen EPS Delivering Every Day
Slide 114: AmerisourceBergen EPS: FY12-FY14
FY12: Retail generic nirvana begins Remember oxy? - It's back in August FY13: Retail generic nirvana continues Business Transformation expense relief Business Transformation benefit FY14: Say hello to the uninsured! Pent-up demand for Rx AmerisourceBergen EPS Delivering Every Day
Slide 115: AmerisourceBergen EPS: FY15
AmerisourceBergen EPS Delivering Every Day FY15: How do you spell biosimilars? Somewhere along the way: Blockbuster introduction(s) Significant at-risk launch New uses for existing drugs
Slide 116: The Best Is Yet to Come!
7 | AmerisourceBergen The Best Is Yet to Come!
Slide 117: Q&A
») AmerisourceBergen Q&A